All questions
Safety: Taltz (ixekizumab) in plaque psoriasis
8 questions · 2 sources
Safety questions that apply to every indication of Taltz are on Taltz (ixekizumab), all indications: Safety.
Side effects
What are the most common side effects of Taltz for plaque psoriasis?
Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Does Taltz cause yeast infections (candidiasis)?
Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Note: The last passage lists postmarketing reports from the Prescribing Information.
Can Taltz cause low white blood cell or platelet counts?
Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Does Taltz cause anti-drug antibodies in plaque psoriasis?
Safety evidence
What are the long-term side effects of Taltz for plaque psoriasis?
Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Note: The table gives incidence rates per 100 patient-years for the total exposure period and then for Years 1 through 5, in the order of the header lines. Above the table, the Taltz HCP adult psoriasis page describes the pooled population as more than 6,800 patients across 15 clinical trials; its safety summary on the same page describes the long-term safety data as an integrated data set of 17 phase 1, 2, 3, and 4 studies in adults with moderate to severe plaque psoriasis, with a March 2022 cutoff.
Warnings
Does Taltz increase the risk of infections?
Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Can Taltz cause Crohn's disease or ulcerative colitis (IBD)?
Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Administration reactions
How common are injection site reactions with Taltz?
Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Note: The 17% and 3% rates are for Taltz 80 mg every 2 weeks and placebo through Week 12 in adults with moderate-to-severe plaque psoriasis, as presented on the Taltz HCP adult psoriasis page.